Quest Diagnostics buys cancer test
This article was originally published in The Gray Sheet
Executive Summary
Firm gains InSure fecal immunochemical colorectal cancer screening test, as well as the InSure II version of the test, cleared by FDA in May for use in doctors' offices, via its $45 mil. purchase of privately held Australian company Enterix. The deal, announced Sept. 7, follows Quest's acquisition of HerpeSelect herpes virus test manufacturer Focus Diagnostics for $185 mil. in July. For the second quarter, Quest reported revenue of $1.6 bil., up 15% from the prior-year period...